In the featured article from the February 2017 issue of The Journal of Nuclear Medicine, researchers document the first-in-human application of a new imaging agent to help find prostate cancer in both early and advanced stages and plan treatment. The study indicates that the new agent—a PET radiotracer—is both safe and effective.
The new agent is a gallium-68 (Ga-68)-labeled peptide BBN-RGD agent that targets both gastrin-releasing peptide receptor (GRPR) and integrin ?v?3. Dual-receptor targeting provides advantages over single-receptor targeting by allowing tumor contrast when either or both receptor types are expressed, improving binding affinity and increasing the number of effective receptors.
Approximately one in seven men will be diagnosed with prostate cancer in his lifetime. In 2017, the American Cancer Society estimates that there will be more than 161,000 new prostate cancer cases in the United States and around 27,000 deaths from the disease. “Although treatable at the early stage, prostate cancer is prone to metastasis,” explain the team of authors, led by Xiaoyuan Chen, senior investigator, Laboratory of Molecular Imaging and Nanomedicine at the U.S. National Institute of Biomedical Imaging and Bioengineering. “An effective and specific imaging method of detecting both primary and metastatic lesions is thus of critical importance to manage patients with prostate cancer.”
This study included 13 patients with prostate cancer (four newly diagnosed and nine post-therapy) and five healthy volunteers. Ga-68-BBN-RGD PET/CT detected 20 bone lesions in seven patients either with primary prostate cancer or after radical prostatectomy. The patients with bone metastases did not necessarily have an elevated prostate specific antigen level. “This result is better than bone scanning with MDP,” Chen notes, referring to the most common radiotracer used today. “MDP bone scans are sensitive but lack specificity because localized skeletal accumulation of Tc-99m-MDP can also be observed in the case of trauma and infection.” No adverse side effects were found during the whole procedure and two-week follow-up, demonstrating the safety of Ga-68-BBN-RGD.
“Compounds capable of targeting more than one biomarker have the ability of binding to both early and metastatic stages of prostate cancer, creating the possibility for a more prompt and accurate diagnostic profile for both primary and the metastatic tumors,” explains Chen.
Looking ahead, Chen says, “Ga-68-BBN-RGD could play an additive role in staging and detecting prostate cancer and provide guidance for internal radiation therapy using the same peptide labeled with therapeutic radionuclides.” He points out that larger-scale clinical investigations are warranted.
Receive an email update when we add a new PROSTATE CANCER article.
The Latest on: Prostate cancer
via Google News
The Latest on: Prostate cancer
- Prostate cancer: New urine test hopeon June 25, 2019 at 7:54 pm
An experimental new urine test can reveal if men with early prostate cancer will probably need aggressive therapy or can be left untreated but monitored, UK researchers say. Current PSA blood tests ... […]
- Urine tests could reveal whether men have prostate cancer five years earlyon June 25, 2019 at 6:00 pm
A SIMPLE urine test can reveal whether men have aggressive prostate cancer five years earlier than currently, researchers claim. It could help thousands get life- saving treatment earlier and spare ... […]
- Prostate of the Nationon June 25, 2019 at 5:11 pm
One day, if Jack lives long enough, I will get cancer. And it could kill us both. But will it? Let’s examine the facts. Prostate cancer is the most common form of cancer for men in the UK, but it does ... […]
- New urine test for prostate cancer ‘has enormous potential’on June 25, 2019 at 4:24 pm
A new urine test for prostate cancer could revolutionise treatment and prevent unnecessary biopsies. The test is much more sensitive than current methods, picking up how aggressive the disease is ... […]
- Simple prostate cancer test could diagnose five years early and prevent thousands of invasive operationson June 25, 2019 at 4:08 pm
A simple urine test could detect aggressive prostate cancer five years before treatment is needed and save thousands of men from invasive surgery. Researchers said the simple test could make a “huge ... […]
- Now there’s a noninvasive treatment for prostate cancer: high-intensity focused ultrasoundon June 25, 2019 at 2:30 pm
Victor Murray has always been proactive about his health. That’s why he never misses his annual physical — and also the reason he wanted to know all of his options when a recent exam revealed an ... […]
- New combo prostate cancer therapy shown safe, effective in trialon June 25, 2019 at 1:08 pm
June 25 (UPI) --A new combination therapy has shown promise in effectively fighting prostate cancer, new research shows. Two targeted treatments reduced PSA levels in patients with prostate cancer and ... […]
- Identification of a Radiosensitivity Molecular Signature Induced by Enzalutamide in Hormone-sensitive and Hormone-resistant Prostate Cancer Cellson June 25, 2019 at 10:42 am
Prostate cancer (PCa) is the most common cancer amongst men. A novel androgen receptor (AR) antagonist, enzalutamide (ENZA) has recently been demonstrated to enhance the effect of radiation (XRT) by ... […]
- New combination therapy established as safe and effective for prostate canceron June 25, 2019 at 9:45 am
A novel therapy using two targeted treatments for prostate cancer has been shown to maximize efficacy while reducing side effects according to research presented at the Society of Nuclear Medicine ... […]
via Bing News